Some genetic polymorphisms of human ABC transporter genes are reportedly related to the risk of certain diseases and patients responses to medication. Human ABCC11 functions as an ATP-dependent efflux pump for amphipathic anions. One nonsynonymous SNP 538G > A (Gly180Arg) has been found to greatly affect the function and stability of de novo synthesized ABCC11 (Arg180) variant protein. The SNP variant lacking N-linked glycosylation is recognized as a misfolded protein in the endoplasmic reticulum (ER) and readily undergoes proteasomal degradation. This ER-associated degradation of ABCC11 protein underlies the molecular mechanism of affecting the function of apocrine glands. On the other hand, the wild type (Gly180) of ABCC11 is associated with wettype earwax, axillary osmidrosis, colostrum secretion from the mammary gland, and the potential susceptibility of breast cancer. Furthermore, the wild type of ABCC11 reportedly has ability to efflux cyclic nucleotides and nucleoside-based anticancer drugs. The SNP (538G > A) of the ABCC11 gene is suggested to be a clinical biomarker for prediction of chemotherapeutic efficacy. Major obstacle to the successful chemotherapy of human cancer is development of resistance, and nucleoside-based chemotherapy is often characterized by inter- individual variability. This review provides an overview about the discovery and the genetic polymorphisms in human ABCC11. Furthermore, we focus on the impact of ABCC11 538G > A on the apocrine phenotype, patients response to nucleoside-based chemotherapy, and the potential risk of breast cancer.